VIDEO: Port delivery system could change treatment burden in nAMD
Click Here to Manage Email Alerts
In this video, Caroline R. Baumal, MD, professor at Tufts University School of Medicine, highlighted data from the Archway study at the virtual American Academy of Ophthalmology annual meeting.
The port delivery system maintained its primary endpoint of vision maintenance and retinal thickness control in patients who had previously received monthly ranibizumab injections. Data showed 98% of patients did not require a supplemental injection and reported a 93% preference of the port delivery system over monthly injections in a clinical setting.
“The port delivery system is really promising to reduce the treatment burden for our patients and be a more durable device. I look forward to seeing what happens over the next year with the port delivery system and whether it gets approved for treatment for our patients,” Baumal told Healio.
Collapse
Holekamp, N, et al. A phase III study to evaluate the port delivery system implant with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration (ARCHWAY). Presented at: AAO20 Virtual Scientific Program; Nov 13-15, 2020.
Read more about
Click Here to Manage Email Alerts